MCI患者血清中Tau蛋白Aβ_(1-42)P-tau的检测价值分析

The value of clinical testing of serum Tau protein,Aβ_(1-42),P-tau in MCI patients

目的探讨血清磷酸化Tau(P-tau)、β淀粉样蛋白1-42(Aβ1-42)以及Tau蛋白在轻度认知障碍(MCI)患者中的临床应用价值。方法采用酶联免疫法测定主诉健忘组(SMC)30例,MCI患者30例,阿尔茨海默病组(AD)68例(轻度AD24例,中度AD 22例,重度AD 22例)以及健康对照组35例血清中P-tau、Aβ1-42、Tau蛋白水平,并分析三种标记物与疾病的相关性。结果与对照组及MCI组相比,MCI组、AD组MMSE评分显著上升,差异有统计学意义(P<0.05),重度AD组MMSE评分显著高于轻度、中度AD组,两两比较差异有统计学意义(P<0.05)。与对照组相比,MCI组、AD组P-tau、Tau蛋白水平显著上升,且AD组高于MCI组,而Aβ1-42水平显著下降,且AD组下降幅度大于MCI组,差异有统计学意义(P<0.05)。其中重度AD组P-tau、Tau蛋白水平高于轻度、中度AD组,而Aβ1-42水平低于轻、中度组,差异有统计学意义(P<0.05)。SMC组与对照组相比,各标记物水平差异无统计学意义(P>0.05)。与单纯Tau蛋白、Aβ1-42、P-tau诊断相比,Tau蛋白、Aβ1-42、P-tau联合诊断的灵敏性、特异性、准确性显著增加,差异有统计学意义(P<0.05)。结论 MCI病情发生及发展过程可能与血清P-tau、Aβ1-42、Tau蛋白水平异常有关,通过测定这三种标记物可有效预测MCI患者病情进展情况。

Objective To investigate the clinical applications of serum phosphorylated Tau （P-tau）,β-amyloid 1-42 （Aβ1-42） and Tau protein in mild cognitive impairment （MCI） patients. Methods The levels of P-tau, Aβ1-42, Tau protein of forgetfulness group （SMC, n=30）, MCI（n=30）, 68cases of Atzheimefs disease group （AD, mild 24 cases, moderate AD cases, severe AD eases） and healthy control group （n= 35） were detected by ELISA determination complained. Results The MMSE scores of MCI group, AD group were higher than that of control group and the MCI group（P〈0.05）. The MMSE scores of severe AD group was significantly higher than that of mild, moderate AD group（P〈0.05）. The levels of P-tau, Tau protein of MCI group, AD group were higher than that of control group（P〈0.05）. The levels of Aβ1-42 of AD group was lower than MCI group（P〈0.05）. The levels of severe AD group was higher than mild, moderate AD group while the levels of Aβ1-42 was lower than mild, moderate AD groups（P〈0.05）. The levels of each marker of SMC were not statistically significant（P~ 0.05）. The sensitivity, specificity, accuracy of Tau protein, Aβ1-42 , P-tau combined diagnostic were higher than Tau protein, Aβ1 42, P-tau（P〈0.05）. Conclusion MCI disease may be associated with the occurrence and development of serum P-tau, Aβ1-42, Tau protein abnormalities; Measurement of these three markers may predict disease progression in patients with MCI.